Crizanlizumab for RVCL
Retinal vasculopathy with cerebral leukoencephalopathy (RVCL) is a very rare and fatal genetic condition that affects the smallest blood vessels, especially of the brain and eye. It causes damage in the brain and eye, and there is currently no treatment to reduce these areas of damage. Crizanlizumab has been shown to treat similar symptoms in other diseases, and it's hypothesized that treating RVCL patients with crizanlizumab will slow the progression of this damage.
Patients diagnosed with retinal vasculopathy with cerebral leukoencephalopathy (RVCL) by Dr. Jonathan Miner at Washington University in St. Louis are being invited to participate in this study at Penn Medicine. Patients that live close to Penn Medicine will be seen by the research team due to proximity of location.
- Study Identifier: 844604
Recruitment StatusEnrolling By Invitation
If you need assistance finding a non-cancer study or if you have any questions, please email firstname.lastname@example.org